Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annu...( ALISO VIEJO Calif. April 23 /- Valean...),Health

ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that results from the week-60 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, was presented today at the European Association for the Study of Liver (EASL) 44th Annual Meeting in Copenhagen, Denmark.

The results were presented in an abstract entitled "Efficacy And Safety of Weight-Based Regimens of Taribavirin or Ribavirin, Given With Peginterferon Alfa-2b, At 12 Weeks After Treatment (SVR12) In Naive Patients With Genotype 1 Chronic-Hepatitis C", with an oral presentation given by Fred Poordad, M.D., Chief of Hepatology at the Center for Liver Disease and Transplant, Cedars-Sinai Medical Center, Los Angeles, CA and principal investigator in this study.

The company previously reported week 12 and 48 results from this Phase IIb trial. The study consists of 48 weeks of treatment with a 24-week post-treatment follow-up period during which period the week 60 results were collected from the arms receiving 20mg/kg and 25mg/kg taribavirin and the ribavirin control arm. Similar to the week 12 and 48 results, the 60-week viral response data continue to show comparable reductions in viral load for weight-based doses of taribavirin and ribavirin in a difficult-to-treat population of subjects infected Hepatitis C genotype 1. At the end of week 60, the statistically significantly lower anemia rate for patients receiving taribavirin in the 20mg/kg and 25mg/kg arms versus the ribavirin control arm has been maintained at a rate similar to the end of treatment (week 48).

    Table:  Efficacy/Safety (intent-to-treat)

                                          Phas
'/>"/>
SOURCE  Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
6. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Genesis Pharmaceuticals Announces the Launch of Three TCM Products